Key Insights

Highlights

Success Rate

90% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.2%

1 terminated out of 24 trials

Success Rate

90.0%

+3.5% vs benchmark

Late-Stage Pipeline

21%

5 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed with results

Key Signals

1 with results90% success

Data Visualizations

Phase Distribution

12Total
Not Applicable (5)
Early P 1 (1)
P 2 (1)
P 3 (2)
P 4 (3)

Trial Status

Completed9
Recruiting5
Unknown5
Not Yet Recruiting2
Active Not Recruiting1
Terminated1

Trial Success Rate

90.0%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT07666269Not ApplicableNot Yet Recruiting

Morphology in Oral Rare Syndromes & Artificial Intelligence for Clinical Diagnosis

NCT06824454Phase 2RecruitingPrimary

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

NCT03771105Early Phase 1RecruitingPrimary

The Impact of Phosphate Metabolism on Healthy Aging

NCT07288944Not ApplicableNot Yet Recruiting

Protocolised Management of Phosphate Replacement Trial

NCT07233889Not ApplicableRecruitingPrimary

Enteral Supplementation With Sodium Dihydrogen Phosphate and Disodium Hydrogen Phosphate Granules for the Treatment of Hypophosphatemia.

NCT06754670Recruiting

Effect of Hypophosphatemia on Neuro-excursion Efficiency During Mechanical Ventilator Weaning

NCT06344546Completed

Metabolic Pathway Analysis in Intensive Care Unit Patients With Refeeding Syndrome

NCT05909722Completed

Validation of the GIDS and Description of Phosphate Disorders

NCT06350955Phase 4RecruitingPrimary

IV Iron-induced Hypophosphatemia After RYGB

NCT06112236Active Not RecruitingPrimary

Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia

NCT05098249Phase 4Completed

Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia

NCT02837523Withdrawn

Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)

NCT03489993CompletedPrimary

FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)

NCT01011114Not ApplicableTerminatedPrimary

Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant

NCT04814641UnknownPrimary

Hypophosphatemia and Bronchiolitis

NCT04519762Phase 4UnknownPrimary

Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU

NCT04502784UnknownPrimary

Investigation of Hypophosphataemia Following Intravenous Iron

NCT03581591Phase 3CompletedPrimary

Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets

NCT03976440Unknown

Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study

NCT03740802CompletedPrimary

Hypophosphatemia as a Predictor in Surgical Resuscitation Sepsis

Scroll to load more

Research Network

Activity Timeline